Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 0.1350 |
| Open | 0.1434 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.1280 - 0.1434 |
| 52 Week Range | 0.0940 - 0.6045 |
| Volume | 277,534 |
| Avg. Volume | 127,716 |
| Market Cap | 38.191M |
| Beta (5Y Monthly) | 2.01 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0290 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
View moreRelated Research
- ACCESSWIRE
Tetra Bio-Pharma Files New Drug Submission for REDUVO(TM) in Canada
* The addressable market is estimated to be $80M CDN by 2022 * Tetra meets another key milestone before the end of the yearOTTAWA, ON / ACCESSWIRE / December 30, 2020 / Tetra Bio-Pharma Inc.
- CNW Group
Staying safe - Top 10 things Ontario doctors are asking you for this holiday season
TORONTO, Dec. 22, 2020 /CNW/ -Â All Ontario doctors want this holiday season is your continued safety and good health.
- ACCESSWIRE
Tetra Bio-Pharma Confirms it is on Track to Receive Government Funding
* Tetra Provides Update on ARDS-003 * Tetra Eyes Global Sepsis MarketOTTAWA, ON / ACCESSWIRE / December 21, 2020 / Tetra Bio-Pharma Inc.
© 2021 Verizon Media. All rights reserved.
